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Discrimination between oral corticosteroid-treated and oral
corticosteroid-non-treated severe asthma patients by an electronic nose
platform
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Rationale: Some severe asthma patients require oral corticosteroids (OCS)
likely due to greater disease severity. Exhaled molecular markers can provide
phenotypic information in asthma.Objectives:Determine whether patients on
OCS (OCS+) have a different breathprint compared with those who were not
on OCS (OCS-); determine the classification accuracy of eNose as compared to
FEV₁ % pred, % sputum eosinophils, and exhaled nitric oxide (FENO).
Methods: This was a cross-sectional analysis of the U-BIOPRED cohort.
Severe asthma was defined by IMI-criteria [Bel Thorax 2011]. OCS+ patients
had daily OCS. OCS- patients had never had OCS and were on maintenance
inhaled fluticasone equivalent >1000 µg/day. Exhaled volatile organic
compounds trapped on adsorption tubes were analysed by centralized eNose
platform (Owlstone Lonestar, Cyranose 320, Comon Invent, Tor Vergata TEN)
including a total of 190 sensors. t test was used for comparing groups and
support vector machine with leave-one-out cross-validation as a classifier.
Results: 33 OCS+ (age 55±11yr, mean±SD, 52% female, 27% smokers, pre-
bronchodilator FEV₁ 64.1±24% pred) and 40 OCS-severe asthma patients (age
54±15yr, mean±SD, 55% female, 35% smokers, pre-bronchodilator FEV₁
61.8±24% pred) were studied. Sensor by sensor analysis showed that 56
sensors provided different mean values (change in sensor resistance or
frequency) between groups (P<0.05). Accuracy of classification was as
follows: eNose 71% (n=73), FENO 71% (n=70), FEV₁ 62% (n=73) and
sputum eosinophils 59% (n=37). Conclusions: Preliminary results suggest
OCS+ and OCS- severe asthma patients can be distinguished by an eNose
platform.
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